Context Therapeutics Inc. CNTX Stock
Context Therapeutics Inc. Price Chart
Context Therapeutics Inc. CNTX Financial and Trading Overview
| Context Therapeutics Inc. stock price | 0.48 USD |
| Previous Close | 0.5 USD |
| Open | 0.51 USD |
| Bid | 0.37 USD x 200 |
| Ask | 0.63 USD x 200 |
| Day's Range | 0.48 - 0.53 USD |
| 52 Week Range | 0.48 - 3.62 USD |
| Volume | 2.41M USD |
| Avg. Volume | 2.43M USD |
| Market Cap | 44.47M USD |
| Beta (5Y Monthly) | 1.745 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.38 USD |
CNTX Valuation Measures
| Enterprise Value | 9.43M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0653987 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.7355623 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.217 |
Trading Information
Context Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | 1.745 |
| 52-Week Change | -16.11% |
| S&P500 52-Week Change | 18.95% |
| 52 Week High | 3.62 USD |
| 52 Week Low | 0.48 USD |
| 50-Day Moving Average | 1.12 USD |
| 200-Day Moving Average | 1.73 USD |
CNTX Share Statistics
| Avg. Volume (3 month) | 2.43M USD |
| Avg. Daily Volume (10-Days) | 1.5M USD |
| Shares Outstanding | 91.88M |
| Float | 48.07M |
| Short Ratio | 1.28 |
| % Held by Insiders | 1.35% |
| % Held by Institutions | 80.13% |
| Shares Short | 6.63M |
| Short % of Float | 8.32% |
| Short % of Shares Outstanding | 7.21% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -35.82% |
| Return on Equity (ttm) | -56.18% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -43500404 USD |
| Net Income Avi to Common (ttm) | -40226928 USD |
| Diluted EPS (ttm) | -0.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 54.53M USD |
| Total Cash Per Share (mrq) | 0.59 USD |
| Total Debt (mrq) | 282.42K USD |
| Total Debt/Equity (mrq) | 0.54 USD |
| Current Ratio (mrq) | 8.955 |
| Book Value Per Share (mrq) | 0.658 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -32786372 USD |
| Levered Free Cash Flow (ttm) | -23796480 USD |
Profile of Context Therapeutics Inc.
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | 2001 Market Street |
| ZIP | 19103 |
| Phone | 267 225 7416 |
| Website | https://www.contexttherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Context Therapeutics Inc. Stock
What is a current CNTX stock price?
Context Therapeutics Inc. CNTX stock price today per share is 0.48 USD.
How to purchase Context Therapeutics Inc. stock?
You can buy CNTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Context Therapeutics Inc.?
The stock symbol or ticker of Context Therapeutics Inc. is CNTX.
Which industry does the Context Therapeutics Inc. company belong to?
The Context Therapeutics Inc. industry is Biotechnology.
How many shares does Context Therapeutics Inc. have in circulation?
The max supply of Context Therapeutics Inc. shares is 91.88M.
What is Context Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Context Therapeutics Inc. PE Ratio is now.
What was Context Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Context Therapeutics Inc. EPS is -0.48 USD over the trailing 12 months.
Which sector does the Context Therapeutics Inc. company belong to?
The Context Therapeutics Inc. sector is Healthcare.
Context Therapeutics Inc. CNTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26690.62 USD — |
+1.3
|
7.21B USD — | 26478.01 USD — | 26712.62 USD — | — - | 7.21B USD — |
|
US Tech Health Care
IXHC
US
|
1293.16 USD — |
+2.08
|
— — | 1273.79 USD — | 1294.2 USD — | — - | — — |
- {{ link.label }} {{link}}
